QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson

CARY, N.C., June 4, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCKTM (ripretinib) for the treatment of adult patients with advanced gastrointestinal ...
Source: McKesson News - Category: Information Technology Source Type: news